Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors
Vall d'Hebron Institute of Oncology is recruiting an early-phase 1 study of ex vivo next-generation neoantigen-selected TIL therapy in advanced epithelial tumors and ICB-resistant solid tumors. The product is an autologous, genetically unmodified TIL preparation enriched for neoantigen reactivity, administered with the standard non-myeloablative lymphodepleting chemotherapy plus IL-2 support described in the protocol background. The signal for the field: neoantigen selection is being applied as a manufacturing enrichment step for TIL-ACT, not just vaccine design, in a solid-tumor population where TIL efficacy remains unproven. Readout is safety and tolerability, an early gate for whether neoantigen-enriched TILs can move beyond melanoma.